Tissue compatibility and pharmacokinetics of three potential subcutaneous injectables for low-pH drug solutions

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 7, 2010, Pages 873-882

  Wu, Zimei ^a   Tucker, Ian G ^b   Razzak, Majid ^c   McSporran, Keith ^d   Medlicott, Natalie J ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c PharmTech Service Limited   (New Zealand)

^d Gribbles Veterinary   (New Zealand)

Author keywords

bioavailability; controlled release; cytotoxicity; poorly soluble drug; postinjection precipitation; tissue tolerance

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALBENDAZOLE SULFOXIDE; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG FORMULATION; HISTOCOMPATIBILITY; MICROEMULSION; MOUSE; NONHUMAN; PH MEASUREMENT; SHEEP;

EID: 77954021008     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.07.0008     Document Type: Article

References (49)

1. Brazeau GA et al. Current perspectives on pain upon injection of drugs. J Pharm Sci 1998 87 : 667 677.
2. Muller RH et al. SolEmuls(R): novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm 2004 269 : 293 302.
3. Lipinski C. Poor aqueous solubility - an industry wide problem in drug discovery. American Pharm Rev 2002 5 : 82 85.
4. Nouws JF et al. A comparative study on irritation and residue aspects of five oxytetracycline formulations administered intramuscularly to calves, pigs and sheep. Vet Quart 1990 12 : 129 138.
5. Brazeau GA, Fung HL. Physicochemical properties of binary organic cosolvent-water mixtures and their relationships to muscle damage following intramuscular injection. J Parenter Sci Technol 1989 43 : 144 149.
6. Brazeau GA, Fung HL. Use of an in vitro model for the assessment of muscle damage from intramuscular injections: in vitro-in vivo correlation and predictability with mixed solvent systems. Pharm Res 1989 6 : 766 771.
7. Brazeau GA, Fung HL. Effect of organic cosolvent-induced skeletal muscle damage on the bioavailability of intramuscular [14C]diazepam. J Pharm Sci 1990 79 : 773 777.
8. Sweetana S, Akers MJ. Solubility principles and practices for parenteral drug dosage form development. PDA J Pharm Sci Technol 1996 50 : 330 342.
9. Simamora P et al. Studies in phlebitis VIII: evaluations of pH solubilized intravenous dexverapamil formulations. PDA J Pharm Sci Technol 1996 50 : 123 128.
10. Nagase Y et al. Inhibitory effect of sulfobutyl ether betacyclodextrin on DY-9760e-induced cellular damage: in vitro and in vivo studies. J Pharm Sci 2003 92 : 2466 2474.
11. Yalkowsky SH, Roseman TJ. Techniques of Solubilization of Drugs: Solubilization of Drugs by Cosolvents.
12. Motola S. Pharmaceutical Dosage Forms, Parenteral Medications: Biopharmaceutics of Injectable Medications, 2nd edn.
13. Tuttle CB. Intramuscular injections and bioavailability. Am J Hosp Pharm 1977 34 : 965 968.
14. Prankerd RJ, Stella VJ. The use of oil-in-water emulsions as a vehicle for parenteral drug administration. J Parenter Sci Technol 1990 44 : 139 149.
15. Prankerd RJ et al. Preliminary development and evaluation of a parenteral emulsion formulation of penclomedine (NSC-338720; 3,5-dichloro-2,4-dimethoxy-6- trichloromethylpyridine): a novel, practically water insoluble cytotoxic agent. J Parenter Sci Technol 1988 42 : 76 81.
16. Park K-M, Kim C-K. Preparation and evaluation of flurbiprofen- loaded microemulsion for parenteral delivery. Int J Pharm 1999 181 : 173 179.
17. Brime B et al. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models. J Antimicrob Chemother 2003 52 : 103 109.
18. Tenjarla S. Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 1999 16 : 461 521.
19. Moreno MA et al. Lecithin-based oil-in-water microemulsions for parenteral use: pseudoternary phase diagrams, characterization and toxicity studies. J Pharm Sci 2003 92 : 1428 1437.
20. Moreno MA et al. Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B. Pharm Res 2001 18 : 344 351.
21. Lee JM et al. Microemulsion formulation of clonixic acid: solubility enhancement and pain reduction. J Pharm Pharmacol 2002 54 : 43 49.
22. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997 86 : 147 162.
23. Medlicott NJ et al. Comparison of the effects of potential parenteral vehicles for poorly water soluble anticancer drugs (organic cosolvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC). J Pharm Sci 1998 87 : 1138 1143.
24. Stella VJ et al. The effect of SBE4-[beta]-CD on i.m. prednisolone pharmacokinetics and tissue damage in rabbits: Comparison to a co-solvent solution and a water-soluble prodrug. Int J Pharm 1995 120 : 197 204.
25. Doenicke A et al. A comparison of two formulations for etomidate, 2-hydroxypropyl-beta-cyclodextrin (HPCD) and propylene glycol. Anesth Analg 1994 79 : 933 939.
26. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996 85 : 1142 1169.
27. McDonald C, Muzumdar PP. Prevention of precipitation of phenytoin in an infusion fluid by hydroxypropyl beta-cyclodextrin. J Clin Pharm Ther 1998 23 : 235 239.
28. Blanchard J et al. Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropylbeta-cyclodextrin. Pharmaceut Dev Tech 2000 5 : 333 338.
29. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008 36 : 30 42.
30. Lanusse CE et al. Ricobendazole kinetics and availability following subcutaneous administration of a novel injectable formulation to calves. Res Vet Sci 1998 65 : 5 10.
31. Cristofol C et al. Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. J Vet Pharmacol Ther 2001 24 : 117 124.
32. Cristofol C et al. Comparative disposition of ricobendazole enantiomers after intravenous and subcutaneous administration of a racemic formulation to calves. Biopharm Drug Dispos 2000 21 : 303 311.
33. Formentini EA et al. Pharmacokinetics of ricobendazole in calves. J Vet Pharmacol Ther 2001 24 : 199 202.
34. Wu Z et al. Physicochemical characterization of ricobendazole. I. Solubility, lipophilicity and ionization characteristics. J Pharm Sci 2005 94 : 983 993.
35. Wu Z et al. An in vitro kinetic method for detection of precipitation of poorly soluble drugs. Int J Pharm 2005 304 : 1 3.
36. Kaartinen L et al. Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxinetrimethoprim containing products after subcutaneous administration in pre-ruminant calves. Vet Res 2000 31 : 517 526.
37. Wu Z et al. Development and optimization of a rapid HPLC method for analysis of ricobendazole and albendazole sulfone in sheep plasma. J Pharm Biomed Anal 2005 39 : 225 232.
38. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis. Concepts and Applications, 3rd edn. Swedish Pharmaceutical Press
39. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004 21 : 201 230.
40. Hem SL et al. Tissue irritation evaluation of potential parenteral vehicles. Drug Dev Commun 1974 1 : 471 477.
41. Howard JR, Hadgraft J. The clearance of oily vehicles following intramuscular and subcutaneous injections in rabbits. Int J Pharm 1983 16 : 31 39.
42. Wade A, Weller PJ. Handbook of Pharmaceutical Excipients.
43. Wilson R, Smith M. Human studies on polyglycerol polyricinoleate (PGPR). Food Chem Toxicol 1998 36 : 743 745.
44. Bjerregaard S et al. Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin. J Control Release 2001 12 : 87 98.
45. Bjerregaard S et al. Parenteral water/oil emulsions containing hydrophilic compounds with enhanced in vivo retention: formulation, rheological characterisation and study of in vivo fate using whole body gamma-scintigraphy. Int J Pharm 2001 14 : 13 27.
46. Macian M et al. Preliminary studies of the toxic effects of nonionic surfactants derived from lysine. Toxicology 1996 106 : 1 9.
47. Watanabe T et al. Utility of MTT assay in three-dimensional cultured human skin model as an alternative for draize skin irritation test: approach using diffusion law of irritant in skin and toxicokinetics-toxicodynamics correlation. Pharm Res 2002 19 : 669 675.
48. Goudah A. Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. Vet Res Commun 2003 27 : 555 566.
49. Benavides T et al. Assessment of primary eye and skin irritants by in vitro cytotoxicity and phototoxicity models: an in vitro approach of new arginine-based surfactant-induced irritation. Toxicology 2004 197 : 229 237.